vs
NEUROCRINE BIOSCIENCES INC（NBIX）与Cloudflare, Inc.（NET）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是Cloudflare, Inc.的1.3倍（$805.5M vs $614.5M），NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -2.0%，领先21.0%），Cloudflare, Inc.同比增速更快（33.6% vs 28.3%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $105.2M），过去两年Cloudflare, Inc.的营收复合增速更高（27.4% vs 25.0%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
Cloudflare是总部位于美国加利福尼亚州旧金山的科技企业，提供内容分发网络（CDN）、云网络安全、DDoS防护等多元互联网服务，同时是ICANN认证的域名注册商。其服务作为网站访客与客户托管服务商之间的反向代理，可有效提升访问性能，抵御恶意流量。
NBIX vs NET — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $614.5M |
| 净利润 | $153.7M | $-12.1M |
| 毛利率 | 97.8% | 73.6% |
| 营业利润率 | 26.2% | -8.0% |
| 净利率 | 19.1% | -2.0% |
| 营收同比 | 28.3% | 33.6% |
| 净利润同比 | 49.1% | 6.0% |
| 每股收益（稀释后） | $1.49 | $-0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $805.5M | $614.5M | ||
| Q3 25 | $794.9M | $562.0M | ||
| Q2 25 | $687.5M | $512.3M | ||
| Q1 25 | $572.6M | $479.1M | ||
| Q4 24 | $627.7M | $459.9M | ||
| Q3 24 | $622.1M | $430.1M | ||
| Q2 24 | $590.2M | $401.0M | ||
| Q1 24 | $515.3M | $378.6M |
| Q4 25 | $153.7M | $-12.1M | ||
| Q3 25 | $209.5M | $-1.3M | ||
| Q2 25 | $107.5M | $-50.4M | ||
| Q1 25 | $7.9M | $-38.5M | ||
| Q4 24 | $103.1M | $-12.8M | ||
| Q3 24 | $129.8M | $-15.3M | ||
| Q2 24 | $65.0M | $-15.1M | ||
| Q1 24 | $43.4M | $-35.5M |
| Q4 25 | 97.8% | 73.6% | ||
| Q3 25 | 98.2% | 74.0% | ||
| Q2 25 | 98.4% | 74.9% | ||
| Q1 25 | 98.4% | 75.9% | ||
| Q4 24 | 98.5% | 76.4% | ||
| Q3 24 | 98.7% | 77.7% | ||
| Q2 24 | 98.4% | 77.8% | ||
| Q1 24 | 98.5% | 77.5% |
| Q4 25 | 26.2% | -8.0% | ||
| Q3 25 | 30.1% | -6.7% | ||
| Q2 25 | 21.2% | -13.1% | ||
| Q1 25 | 4.1% | -11.1% | ||
| Q4 24 | 22.6% | -7.5% | ||
| Q3 24 | 29.5% | -7.2% | ||
| Q2 24 | 24.6% | -8.7% | ||
| Q1 24 | 19.3% | -14.4% |
| Q4 25 | 19.1% | -2.0% | ||
| Q3 25 | 26.4% | -0.2% | ||
| Q2 25 | 15.6% | -9.8% | ||
| Q1 25 | 1.4% | -8.0% | ||
| Q4 24 | 16.4% | -2.8% | ||
| Q3 24 | 20.9% | -3.6% | ||
| Q2 24 | 11.0% | -3.8% | ||
| Q1 24 | 8.4% | -9.4% |
| Q4 25 | $1.49 | $-0.03 | ||
| Q3 25 | $2.04 | $0.00 | ||
| Q2 25 | $1.06 | $-0.15 | ||
| Q1 25 | $0.08 | $-0.11 | ||
| Q4 24 | $1.00 | $-0.05 | ||
| Q3 24 | $1.24 | $-0.04 | ||
| Q2 24 | $0.63 | $-0.04 | ||
| Q1 24 | $0.42 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $943.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.3B | $1.5B |
| 总资产 | $4.6B | $6.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $713.0M | $943.5M | ||
| Q3 25 | $340.2M | $1.1B | ||
| Q2 25 | $264.0M | $1.5B | ||
| Q1 25 | $194.1M | $204.5M | ||
| Q4 24 | $233.0M | $147.7M | ||
| Q3 24 | $349.1M | $182.9M | ||
| Q2 24 | $139.7M | $157.0M | ||
| Q1 24 | $396.3M | $254.4M |
| Q4 25 | $3.3B | $1.5B | ||
| Q3 25 | $3.0B | $1.3B | ||
| Q2 25 | $2.7B | $1.2B | ||
| Q1 25 | $2.5B | $1.4B | ||
| Q4 24 | $2.6B | $1.0B | ||
| Q3 24 | $2.7B | $973.1M | ||
| Q2 24 | $2.5B | $881.5M | ||
| Q1 24 | $2.4B | $797.2M |
| Q4 25 | $4.6B | $6.0B | ||
| Q3 25 | $4.3B | $5.8B | ||
| Q2 25 | $3.9B | $5.6B | ||
| Q1 25 | $3.7B | $3.7B | ||
| Q4 24 | $3.7B | $3.3B | ||
| Q3 24 | $3.5B | $3.1B | ||
| Q2 24 | $3.3B | $2.9B | ||
| Q1 24 | $3.5B | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $190.4M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $105.2M |
| 自由现金流率自由现金流/营收 | 47.9% | 17.1% |
| 资本支出强度资本支出/营收 | 0.3% | 13.9% |
| 现金转化率经营现金流/净利润 | 2.53× | — |
| 过去12个月自由现金流最近4个季度 | $743.9M | $287.5M |
8季度趋势，按日历期对齐
| Q4 25 | $388.4M | $190.4M | ||
| Q3 25 | $227.5M | $167.1M | ||
| Q2 25 | $102.0M | $99.8M | ||
| Q1 25 | $64.8M | $145.8M | ||
| Q4 24 | $242.5M | $127.3M | ||
| Q3 24 | $158.0M | $104.7M | ||
| Q2 24 | $64.6M | $74.8M | ||
| Q1 24 | $130.3M | $73.6M |
| Q4 25 | $386.0M | $105.2M | ||
| Q3 25 | $214.3M | $82.5M | ||
| Q2 25 | $89.5M | $39.9M | ||
| Q1 25 | $54.1M | $59.9M | ||
| Q4 24 | $235.2M | $54.2M | ||
| Q3 24 | $149.9M | $54.5M | ||
| Q2 24 | $53.0M | $45.2M | ||
| Q1 24 | $119.1M | $41.5M |
| Q4 25 | 47.9% | 17.1% | ||
| Q3 25 | 27.0% | 14.7% | ||
| Q2 25 | 13.0% | 7.8% | ||
| Q1 25 | 9.4% | 12.5% | ||
| Q4 24 | 37.5% | 11.8% | ||
| Q3 24 | 24.1% | 12.7% | ||
| Q2 24 | 9.0% | 11.3% | ||
| Q1 24 | 23.1% | 11.0% |
| Q4 25 | 0.3% | 13.9% | ||
| Q3 25 | 1.7% | 15.1% | ||
| Q2 25 | 1.8% | 11.7% | ||
| Q1 25 | 1.9% | 17.9% | ||
| Q4 24 | 1.2% | 15.9% | ||
| Q3 24 | 1.3% | 11.7% | ||
| Q2 24 | 2.0% | 7.4% | ||
| Q1 24 | 2.2% | 8.5% |
| Q4 25 | 2.53× | — | ||
| Q3 25 | 1.09× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 8.20× | — | ||
| Q4 24 | 2.35× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 0.99× | — | ||
| Q1 24 | 3.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
NET
| Sales Channel Directly To Consumer | $438.5M | 71% |
| Sales Channel Through Intermediary | $176.0M | 29% |
